TCD601

Phase 2Biologic

IITB-Med LLC

TCD601 is one of 100 biologic programs targeting Liver Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver TransplantActive, not recruiting

Amyotrophic Lateral SclerosisActive, not recruiting

Type 1 DiabetesActive, not recruiting

KidneyTerminated

Liver TransplantPhase 2

Active, not recruiting

Amyotrophic Lateral SclerosisPhase 1

Active, not recruiting

Type 1 DiabetesPhase 2

Active, not recruiting

KidneyPhase 2

Terminated

Competition

Competitive Landscape

384 competitors in Type 1 Diabetes

#DrugCompanyPhaseTrials

TCD601

IITB-Med LLC

Phase 2

1 2

Symlin

AstraZeneca

Preclinical

4 3

Symlin

AstraZeneca

Preclinical

3 4

Aldomet

Neurocrine Biosciences

Preclinical

2 5

Glargine

Eli Lilly

Preclinical

4 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Foradil

Viatris

Preclinical

1 8

SGLT2 Inhibitor

Eli Lilly

Preclinical

1 9

Teplizumab

Sanofi

Preclinical

8 10

Mesenchymal Stem Cells

JJiangsu Topcel-KH Pharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Amyotrophic Lateral Sclerosis

NCT06453668

Q2 2029

Phase 2Active, not recruiting

Liver Transplant

NCT06019507

Clinical

Trials by Indication[1]

De Novo Renal Transplantation2 trials

A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation

Terminated·IITB-Med LLC·Phase 2·NCT06365437·33 enrolled

A Dose Escalation Study in de Novo Renal Transplantation

Completed·IITB-Med LLC·Phase 2·NCT04311632·13 enrolled

Renal Transplant Recipients1 trial

A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruiting·IITB-Med LLC·Phase 2·NCT05669001·76 enrolled

Amyotrophic Lateral Sclerosis1 trial

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Active, not recruiting·IITB-Med LLC·Phase 1·NCT06453668·48 enrolled

Renal Transplantation1 trial

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Terminated·IITB-Med LLC·Phase 2·NCT04803006·4 enrolled

Type 1 Diabetes1 trial

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

Terminated·IITB-Med LLC·Phase 2·NCT06025110·9 enrolled

2 more indications

Liver Transplant1 trial

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active, not recruiting·IITB-Med LLC·Phase 2·NCT06019507·12 enrolled

Kidney1 trial

A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including Fludarabine and Cyclophosphamide, for Tolerance Induction in Living Donor Renal Transplantation

Terminated·IITB-Med LLC·Phase 2·NCT04803058·7 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for TCD601. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TCD601 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TCD601. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ITB-Med LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: IITB-Med LLC

TCD601

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2029

Trials by Indication[1]

De Novo Renal Transplantation2 trials

Renal Transplant Recipients1 trial

Amyotrophic Lateral Sclerosis1 trial

Renal Transplantation1 trial

Type 1 Diabetes1 trial

Liver Transplant1 trial

Kidney1 trial

References

Drug Info

Quick Facts

Related News